BOSTON--(BUSINESS WIRE)--Jul. 27, 2016--
Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing
innovative and proprietary treatments for nocturnal leg cramps (NLC),
cramps and spasms associated with severe neuromuscular conditions such
as MS and ALS, and exercise-associated muscle cramps, announced today
that it will report its financial results for the second quarter ended
June 30, 2016 on Wednesday, August 3, 2016 before the U.S. financial
markets open. The Company will host a conference call and webcast at
8:45 a.m. ET to discuss second quarter 2016 financial results and
provide a business update. Individuals interested in participating in
the call should dial (855) 780-7202 (U.S. and Canada) or (631) 485-4874
A live webcast may be accessed in the Investors section of the Company's
website at www.flex-pharma.com.
Please log on to the Flex Pharma website approximately 15 minutes prior
to the scheduled webcast to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be
available on Flex Pharma's website for three months.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing
innovative and proprietary treatments for nocturnal leg cramps, cramps
and spasms associated with severe neuromuscular conditions such as MS
and ALS, and exercise-associated muscle cramps. Flex Pharma was founded
by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel
Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of
ion channels and neurobiology, along with Chair and CEO Christoph
Westphal, M.D., Ph.D.
for updates and to learn more about HOTSHOT™, the Company’s
consumer product which is scientifically proven to prevent and treat
HOTSHOT is a consumer product that is marketed to endurance athletes for
exercise-associated muscle cramps. HOTSHOT complements the Company’s
drug development business and is not intended to diagnose, treat, cure
or prevent any disease.
Follow Flex Pharma (@flexpharma) and HOTSHOTTM
(@Team_HOTSHOT) on Twitter
View source version on businesswire.com: http://www.businesswire.com/news/home/20160727005207/en/
Source: Flex Pharma, Inc.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Relations & Corporate Communications